Extracellular Hsp90 (eHsp90) as the Actual Target in Clinical Trials. Intentionally or Unintentionally

International Review of Cell and Molecular Biology

Volumn 303, Issue , 2013, Pages 203-235

  Li, Wei ^a   Tsen, Fred ^a   Sahu, Divya ^a   Bhatia, Ayesha ^a   Chen, Mei ^a   Multhoff, Gabriele ^b   Woodley, David T ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

17 AAG; Cancer progression; Cell motility; EHsp90; Hsp90; Wound healing

Indexed keywords

17 N ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BORTEZOMIB; CNF 2024; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; LUMINESPIB; RETASPIMYCIN; SNX 5422; STA 909; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER PATIENT; CELL INVASION; CELL MOTILITY; CIRCULATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; ENVIRONMENTAL STRESS; GASTROINTESTINAL STROMAL TUMOR; GROWTH CURVE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SCIENTIST; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 84874256983     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407697-6.00005-2     Document Type: Chapter

References (102)

1. Bandyopadhyay B., Fan J., Guan S., Li Y., Chen M., Woodley D.T., Li W. A "traffic control" role for TGFbeta3: orchestrating dermal and epidermal cell motility during wound healing. J. Cell. Biol. 2006, 172:1093-1105.
2. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res. 2009, 15:9-14.
3. Basu S., Binder R.J., Suto R., Anderson K.M., Srivastava P.K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 2000, 12:1539-1546.
4. Binder R.J., Vatner R., Srivastava P. The heat-shock protein receptors: some answers and more questions. Tissue Antigens 2004, 64:442-451.
5. Bouchier-Hayes L., Oberst A., McStay G.P., Connell S., Tait S.W., Dillon C.P., Flanagan J.M., Beere H.M., Green D.R. Characterization of cytoplasmic caspase-2 activation by induced proximity. Mol. Cell. 2009, 35:830-840.
6. Cecchini P., Tavano R., Polverino de Laureto P., Franzoso S., Mazzon C., Montanari P., Papini E. The soluble recombinant Neisseria meningitidis adhesin NadA Δ351-405 stimulates human monocytes by binding to extracellular Hsp90. PLoS One 2011, 6:e25089.
7. Chatterjee M., Jain S., Stühmer T., Andrulis M., Ungethüm U., Kuban R.J., Lorentz H., Bommert K., Topp M., Krämer D., Müller-Hermelink H.K., Einsele H., Greiner A., Bargou R.C. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007, 109:720-728.
8. Chen J.S., Hsu Y.M., Chen C.C., Chen L.L., Lee C.C., Huang T.S. Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression. J. Biol. Chem. 2010, 285:25458-25466.
9. Cheng C.F., Fan J., Fedesco M., Guan S., Li Y., Bandyopadhyay B., Bright A.M., Yerushalmi D., Liang M., Chen M., Han Y.P., Woodley D.T., Li W. Transforming growth factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich environment during wound healing. Mol. Cell. Biol. 2008, 28:3344-3358.
10. Cheng C.F., Fan J., Zhao Z., T Woodley D., Li W. Secreted heat shock Protein-90: a more effective and safer target for anti-cancer drugs?. Curr. Signal Transduct. Ther. 2010, 5:121-127.
11. Cheng C.F., Sahu D., Tsen F., Zhao Z., Fan J., Kim R., Wang X., O'Brien K., Li Y., Kuang Y., Chen M., Woodley D.T., Li W. A fragment of secreted Hsp90α carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice. J. Clin. Invest. 2011, 121:4348-4361.
12. Chung Y.L., Troy H., Banerji U., Jackson L.E., Walton M.I., Stubbs M., Griffiths J.R., Judson I.R., Leach M.O., Workman P., Ronen S.M. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl. Cancer Inst. 2003, 95:1624-1633.
13. Clayton A., Turkes A., Navabi H., Mason M.D., Tabi Z. Induction of heat shock proteins in B-cell exosomes. J. Cell. Sci. 2005, 118:3631-3638.
14. Csermely P., Schnaider T., Soti C., Prohászka Z., Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 1998, 79:129-168.
15. Didelot C., Lanneau D., Brunet M., Bouchot A., Cartie J., Jacquel A., Ducoroy P., Cathelin S., Decologne N., Chiosis G., Dubrez-Daloz L., Solary E., Garrido C. Interaction of heat-shock protein 90 beta isoform (HSP90 beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. Cell. Death Differ. 2008, 15:859-866.
16. Dvorack H.F. Tumors: wounds that do not heal. The New Eng. J. Med. 1986, 315:1650-1659.
17. Drysdale M.J., Brough P.A., Massey A., Jensen M.R., Schoepfer J. Targeting Hsp90 for the treatment of cancer. Curr. Opin. Drug Discov. Devel. 2006, 9:483-495.
18. Egorin M.J., Rosen D.M., Wolff J.H., Callery P.S., Musser S.M., Eiseman J.L. Metabolism of 17-allylamino-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res. 1998, 58:2385-2396.
19. Eiseman J.L., Lan J., Lagattuta T.F., Hamburger D.R., Joseph E., Covey J.M., Egorin M.J. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino] geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 2005, 55:21-32.
20. Eustace B.K., Jay D.G. Extracellular roles for the molecular chaperone, hsp90. Cell Cycle 2004, 3:1098-1100.
21. Eustace B.K., Sakurai T., Stewart J.K., Yimlamai D., Unger C., Zehetmeier C., Lain B., Torella C., Henning S.W., Beste G., Scroggins B.T., Neckers L., Ilag L.L., Jay D.G. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell. Biol. 2004, 6:507-514.
22. Ferrarini M., Heltai S., Zocchi M.R., Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int. J. Cancer 1992, 51:613-619.
23. Fredly H., Reikvam H., Gjertsen B.T., Bruserud O. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Am. J. Hematol. 2012, 87:368-376.
24. Février B., Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell. Biol. 2004, 16:415-421.
25. Gopal U., Bohonowych J.E., Lema-Tome C., Liu A., Garrett-Mayer E., Wang B., Isaacs J.S. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS One 2011, 6:e17649.
26. Grad I., Cederroth C.R., Walicki J., Grey C., Barluenga S., Winssinger N., De Massy B., Nef S., Picard D. The molecular chaperone Hsp90α is required for meiotic progression of spermatocytes beyond pachytene in the mouse. PLoS One 2010, 5:e15770.
27. Hacker S., Lambers C., Hoetzenecker K., Pollreisz A., Aigner C., Lichtenauer M., Mangold A., Niederpold T., Zimmermann M., Taghavi S., Klepetko W., Ankersmit H.J. Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction. Clin. Lab. 2009, 55:31-40.
28. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
29. Herz J., Strickland D.K. LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 2001, 108:779-784.
30. Hightower L.E., Guidon P.T. Selective release from cultured mammalian cells of heat-shock stress proteins that resemble glia-axon transfer proteins. J. Cell. Physiol. 1989, 138:257-266.
31. Horwich A.L., Neupert W., Hartl F.U. Protein-catalysed protein folding. Trends Biotechnol. 1990, 8:126-131.
32. Houlihan J.L., Metzler J.J., Blum J.S. HSP90alpha and HSP90beta isoforms selectively modulate MHC class II antigen presentation in B cells. J. Immunol. 2009, 182:7451-7458.
33. Hung C.Y., Tsai M.C., Wu Y.P., Wang R.Y. Identification of heat-shock protein 90 beta in Japanese encephalitis virus-induced secretion proteins. J. Gen. Virol. 2011, 92:2803-2809.
34. Imai T., Kato Y., Kajiwara C., Mizukami S., Ishige I., Ichiyanagi T., Hikida M., Wang J.Y., Udono H. Heat shock protein 90 HSP90 contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells. Proc. Natl. Acad. Sci. USA 2011, 108:16363-16368.
35. Isaacs J.S., Xu W., Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3:213-217.
36. Kajiwara C., Kondo S., Uda S., Dai L., Ichiyanagi T., Chiba T., Ishido S., Koji T., Udono H. Spermatogenesis arrest caused by conditional deletion of Hsp90α in adult mice. Biol. Open 2012, 1:977-982.
37. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
38. Kunisawa J., Shastri N. Hsp90alpha chaperones large C-terminally extended proteolytic intermediates in the MHC class I antigen processing pathway. Immunity 2006, 24:523-534.
39. Kuo C.C., Liang C.M., Lai C.Y., Liang S.M. Involvement of heat shock protein Hsp90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide. J. Immunol. 2007, 178:6100-6108.
40. Kuroita T., Tachibana H., Ohashi H., Shirahata S., Murakami H. Growth stimulating activity of heat shock protein 90 alpha to lymphoid cell lines in serum-free medium. Cytotechnology 1992, 8:109-117.
41. Lancaster G.I., Febbraio M.A. Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J. Biol. Chem. 2005, 280:23349-23355.
42. Lee E.J., Lim J.Y., Lee S.Y., Lee S.H., In K.H., Yoo S.H., Sul D., Park S. The expression of HSPs, anti-oxidants, and cytokines in plasma and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Clin. Biochem. 2012, 45:493-498.
43. Li W., Li Y., Guan S., Fan J., Cheng C.F., Bright A.M., Chinn C., Chen M., Woodley D.T. Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. EMBO J. 2007, 26:1221-1233.
44. Li Y., Li S., Hoshino M., Ishikawa R., Kajiwara C., Gao X., Zhao Y., Ishido S., Udono H., Wang J.Y. HSP90α deficiency does not affect Ig gene hypermutation and class switch but causes enhanced MHC class II antigen presentation. Int. Immunol. 2012, [Epub ahead of print].
45. Li W., Sahu D., Tsen F. Secreted heat shock protein-90 Hsp90 in wound healing and cancer. Biochim. Biophys. Acta 2012, 1823:730-741.
46. Liao D.F., Jin Z.G., Baas A.S., Daum G., Gygi S.P., Aebersold R., Berk B.C. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J. Biol. Chem. 2000, 275:189-196.
47. Lillis A.P., Van Duyn L.B., Murphy-Ullrich J.E., Strickland D.K. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 2008, 88:887-918.
48. Mandracchia V.J., Sanders S.M., Frerichs J.A. The use of becaplermin rhPDGF-BB gel for chronic nonhealing ulcers. A retrospective analysis. Clin. Podiatr. Med. Surg. 2001, 18:189-209. (viii).
49. Martin P. Wound healing-aiming for perfect skin regeneration. Science 1997, 276:75-81.
50. McClellan A.J., Xia Y., Deutschbauer A.M., Davis R.W., Gerstein M., Frydman J. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 2007, 131:121-135.
51. McCready J., Sims J.D., Chan D., Jay D.G. Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer 2010, 10:294.
52. Metchat A., Akerfelt M., Bierkamp C., Delsinne V., Sistonen L., Alexandre H., Christians E.S. Mammalian heat shock factor 1 is essential for oocyte meiosis and directly regulates Hsp90alpha expression. J. Biol. Chem. 2009, 284:9521-9528.
53. Miyata Y., Nakamoto H., Neckers L. The therapeutic target hsp90 and cancer hallmarks. Curr. Pharm. Des.19 2013, 347-365.
54. Modi S., Stopeck A., Linden H., Solit D., Chandarlapaty S., Rosen N., D'Andrea G., Dickler M., Moynahan M.E., Sugarman S., Ma W., Patil S., Norton L., Hannah A.L., Hudis C. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin 17-AAG plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 2011, 17:5132-5139.
55. Multhoff G., Hightower L.E. Cell surface expression of heat shock proteins and the immune response. Cell Stress Chaperones 1996, 1:167-176.
56. Musiał K., Szczepańska M., Szprynger K., Zwolińska D. The impact of dialysis modality on serum heat shock proteins in children and young adults with chronic kidney disease. Kidney Blood Press. Res. 2009, 32:366-372.
57. Musiał K., Szprynger K., Szczepańska M., Zwolińska D. Heat shock proteins in children and young adults on chronic hemodialysis. Pediatr. Nephrol. 2009, 24:2029-2034.
58. Nagai M.K., Embil J.M. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin. Biol. Ther. 2002, 2:211-218.
59. Neckers L., Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin. Emerg. Drugs 2002, 7:277-288.
60. Obermann W.M., Sondermann H., Russo A.A., Pavletich N.P., Hartl F.U. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J. Cell. Biol. 1998, 143:901-910.
61. Picard D. Preface to hsp90. Biochim. Biophys. Acta 2012, 1823:605-606.
62. Powers M.V., Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr. Relat. Cancer 2006, 13(Suppl. 1):S125-S135.
63. Ritossa F. Discovery of the heat shock response. Cell Stress Chaperones 1996, 1:97-98.
64. Sahu D., Zhao Z., Tsen F., Cheng C.F., Park R., Situ A.J., Dai J., Eginli A., Shams S., Chen M., Ulmer T.S., Conti P., Woodley D.T., Li W. A potentially common peptide target in secreted heat shock protein-90α for hypoxia-inducible factor-1α-positive tumors. Mol. Biol. Cell. 2012, 23:602-613.
65. Saribek B., Jin Y., Saigo M., Eto K., Abe S. HSP90beta is involved in signaling prolactin-induced apoptosis in newt testis. Biochem. Biophys. Res. Commun. 2006, 349:1190-1197.
66. Sarkar A.A., Zohn I.E. Hectd1 regulates intracellular localization and secretion of Hsp90 to control cellular behavior of the cranial mesenchyme. J. Cell. Biol. 2012, 196:789-800.
67. Savina A., Furlán M., Vidal M., Colombo M.I. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J. Biol. Chem. 2003, 278:20083-20090.
68. Schmitt E., Gehrmann M., Brunet M., Multhoff G., Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leukoc. Biol. 2007, 81:15-27.
69. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 2007, 12:853-859.
70. Semenza G.L. Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148:399-408.
71. Semenza G.L. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol. Med. 2012, 18:534-543.
72. Sidera K., Samiotaki M., Yfanti E., Panayotou G., Patsavoudi E. Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J. Biol. Chem. 2004, 279:45379-45388.
73. Sidera K., Gaitanou M., Stellas D., Matsas R., Patsavoudi E. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J. Biol. Chem. 2008, 283:2031-2041.
74. Sims J.D., McCready J., Jay D.G. Extracellular heat shock protein Hsp 70 and Hsp90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One 2011, 6:e18848.
75. Singer A.J., Clark R.A. Cutaneous wound healing. N. Engl. J. Med. 1999, 341:738-746.
76. Song X., Wang X., Zhuo W., Shi H., Feng D., Sun Y., Liang Y., Fu Y., Zhou D., Luo Y. The regulatory mechanism of extracellular Hsp90α on matrix metalloproteinase-2 processing and tumor angiogenesis. J. Biol. Chem. 2010, 285:40039-40049.
77. Sreedhar A.S., Kalmár E., Csermely P., Shen Y.F. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004, 562:11-15.
78. Stellas D., El Hamidieh A., Patsavoudi E. Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell. Biol. 2010, 11:51.
79. Stellas D., Karameris A., Patsavoudi E. Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin. Cancer Res. 2007, 13:1831-1838.
80. Stoorvogel W., Kleijmeer M.J., Geuze H.J., Raposo G. The biogenesis and functions of exosomes. Traffic 2002, 3:321-330.
81. Strickland D.K., Ashcom J.D., Williams S., Burgess W.H., Migliorini M., Argraves W.S. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J. Biol. Chem. 1990, 265:17401-17404.
82. Sun Y., Zang Z., Xu X., Zhang Z., Zhong L., Zan W., Zhao Y., Sun L. Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry. Int. J. Mol. Sci. 2010, 11:1423-1433.
83. Suzuki S., Kulkarni A.B. Extracellular heat shock protein HSP90beta secreted by MG63 osteosarcoma cells inhibits activation of latent TGF-beta1. Biochem. Biophys. Res. Commun. 2010, 398:525-531.
84. Théry C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2:569-579.
85. Tsutsumi S., Mollapour M., Graf C., Lee C.T., Scroggins B.T., Xu W., Haslerova L., Hessling M., Konstantinova A.A., Trepel J.B., Panaretou B., Buchner J., Mayer M.P., Prodromou C., Neckers L. Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nat. Struct. Mol. Biol. 2009, 16:1141-1147.
86. Tsutsumi S., Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci. 2007, 98:1536-1539.
87. Tsutsumi S., Scroggins B., Koga F., Lee M.J., Trepel J., Felts S., Carreras C., Neckers L. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2008, 27:2478-2487.
88. Vilenchik M., Solit D., Basso A., Huezo H., Lucas B., He H., Rosen N., Spampinato C., Modrich P., Chiosis G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. 2004, 11:787-797.
89. Voss A.K., Thomas T., Gruss P. Mice lacking HSP90beta fail to develop a placental labyrinth. Development 2000, 127:1-11.
90. Wang X., Heuvelman D.M., Carroll J.A., Dufield D.R., Masferrer J.L. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells. Cancer Invest. 2010, 28:635-641.
91. Wang X., Song X., Zhuo W., Fu Y., Shi H., Liang Y., Tong M., Chang G., Luo Y. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:21288-21293.
92. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.
93. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., Neckers L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8324-8328.
94. Whitesell L., Santagata S., Lin N.U. Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution. Curr. Mol. Med. 2012, 12(9):1108-1124. Nov 1.
95. Woodley D.T., Fan J., Cheng C.F., Li Y., Chen M., Bu G., Li W. Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90alpha autocrine signaling to promote keratinocyte migration. J. Cell. Sci. 2009, 122:1495-1498.
96. Workman P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. 2004, 10:47-51.
97. Workman P., Burrows F., Neckers L., Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. N. Y. Acad. Sci. 2007, 1113:202-216.
98. Yang C., Robbins P.D. The roles of tumor-derived exosomes in cancer pathogenesis. Clin. Dev. Immunol. 2011, 2011:842849.
99. Young J.C., Moarefi I., Hartl F.U. Hsp90: a specialized but essential protein-folding tool. J. Cell. Biol. 2001, 154:267-273.
100. Yu X., Harris S.L., Levine A.J. The regulation of exosome secretion: a novel function of the p.53 protein. Cancer Res. 2006, 66:4795-4801.
101. Zagouri F., Sergentanis T.N., Provatopoulou X., Kalogera E., Chrysikos D., Lymperi M., Papadimitriou C.A., Zografos E., Bletsa G., Kalles V.S., Zografos G.C., Gounaris A. Serum levels of HSP90 in the continuum of breast ductal and lobular lesions. In Vivo 2011, 25:669-672.
102. Zurawska A., Urabnski J., Bieganowski P. Hsp90n - an accidental product of a fortuitous chromosomal translocation rather than a regular Hsp90 family member of human proteome. Biochim. Biophys. Acta 2008, 1784:1844-1846.